Tag: Opdivo
Long-Term Survival Benefit Seen for Nivolumab in Advanced Melanoma
Continued survival benefit seen for nivolumab plus ipilimumab and for nivolumab monotherapy versus ipilimumab monotherapy
FDA Approves Nivolumab as Adjuvant Treatment for Melanoma
Approval granted for patients aged 12 years and older with stage IIB/C disease
Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer
Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse
AACR: Adding Nivolumab to Neoadjuvant Chemo Slows Resectable NSCLC
Event-free survival prolonged and percentage of patients with a pathological complete response higher with addition of nivolumab
Nivolumab Combo Treats Advanced Esophageal Squamous-Cell Carcinoma
Overall survival longer in patients receiving first-line treatment with nivolumab plus chemo or nivolumab plus ipilimumab versus chemo alone
Adjuvant Nivolumab Slows Muscle-Invasive Urothelial Carcinoma
Disease-free survival was longer with adjuvant nivolumab in intention-to-treat population, for those with PD-L1 expression at least 1 percent
CDC: 2013 to 2018 Saw Jump in Drug OD Deaths Involving Cocaine
Nivolumab Therapy Prolongs Survival in Advanced Melanoma
Nivolumab + Ipilimumab Shows Efficacy for Untreated Brain Mets
